TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17442687

Group type: EXPERIMENTAL
Intervention: Etoricoxib (120 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study: 15077073

Group type: EXPERIMENTAL
Intervention: Conjugate vaccine
Number of subjects: 83
Study: 12585000

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aqueous nasal spray (400 micrograms daily for 6 weeks for isolated rhinitis and 6 months for associated forms)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 88
Study: 9519052

Group type: EXPERIMENTAL
Intervention: CT with 1 mm collimation and pitch 2.0
Number of subjects: 40

Group type: COMPARATOR
Intervention: CT with 1 mm collimation and pitch 1.0
Number of subjects: 40

Group type: COMPARATOR
Intervention: CT with collimation of 3 mm or higher
Number of subjects: 40
Study: 7978005

Group type: EXPERIMENTAL
Intervention: Postcholecystectomy patients (symptomatic)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Postcholecystectomy patients (asymptomatic)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy volunteers (normals)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Symptomatic postcholecystectomy patients
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Asymptomatic postcholecystectomy patients
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Postcholecystectomy patients
Number of subjects: 16
Study: 2563741

Group type: EXPERIMENTAL
Intervention: Single photon emission computed tomography (SPECT)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Planar imaging
Number of subjects: 135
Study: 787958

Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg per day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30769263

Group type: EXPERIMENTAL
Intervention: Integrated Cognitive Behavioral Therapy (CBT/Integrated) - 15 individual sessions including motivational therapy, coping skills training, relapse prevention for SUD, and ADHD skills training
Number of subjects: 119

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy directed at SUD only (CBT/SUD) - 10 individual SUD treatment sessions
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Integrated Cognitive Behavioral Therapy (CBT/Integrated)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy directed at SUD only (CBT/SUD)
Number of subjects: 119
Study: 28542447

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 25939711

Group type: EXPERIMENTAL
Intervention: 1 g metformin twice daily
Number of subjects: 34
Study: 24152839

Group type: EXPERIMENTAL
Intervention: Berberis aristata/Silybum marianum
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 21737373

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of rhLFA3‐IgFP (15 mg/week)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Oral administration of blank dummy methotrexate (7.5 mg/week)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control group received oral methotrexate (7.5 mg/week) and intramuscular injection of blank dummy rhLFA3‐IgFP (15 mg/week)
Number of subjects: 212
Study: 19335890

Group type: EXPERIMENTAL
Intervention: Multidisciplinary lifestyle intervention including physical activity lessons, nutrition education, and reduced media use over one school year.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 40
Study: 17521477

Group type: EXPERIMENTAL
Intervention: Individuals with TBI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Significant Others (SO)
Number of subjects: 0
Study: 15456674

Group type: EXPERIMENTAL
Intervention: Stress Management Training (SMT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Progressive Muscular Relaxation (PMR)
Number of subjects: 44
Study: 11519634

Group type: COMPARATOR
Intervention: Diazepam 0 mg (placebo)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Diazepam 20 mg
Number of subjects: 5
Study: 9737832

Group type: EXPERIMENTAL
Intervention: Filgrastim 75 microg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Filgrastim 150 microg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Filgrastim 300 microg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Filgrastim 600 microg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7918915

Group type: EXPERIMENTAL
Intervention: Gore‐Tex membrane treatment
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control treatment (no Gore‐Tex membrane)
Number of subjects: 6
Study: 3339821

Group type: EXPERIMENTAL
Intervention: Intervention patients (predictions provided by computer)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control patients (no predictions provided)
Number of subjects: 112
Study: 31401340

Group type: EXPERIMENTAL
Intervention: 5% povidone-iodine (5% PVP-I)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Preservative free artificial tears (AT)
Number of subjects: 56
Study: 28716684

Group type: EXPERIMENTAL
Intervention: Retrobulbar injection (1–2 mL; 15 orbits)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Medial canthal peribulbar injection (2–8 mL; PB-1; 16 orbits)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dorsomedial and ventrolateral peribulbar injections (each 1–4 mL; PB-2; 16 orbits)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 24
Study: 26337247

Group type: EXPERIMENTAL
Intervention: Vibration device (80 Hz, 5 minutes daily for 6 months)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Vibration device (80 Hz)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Both groups (Vibration and Placebo)
Number of subjects: 109
Study: 23222369

Group type: EXPERIMENTAL
Intervention: MRC Chemotherapy + ATRA
Number of subjects: 285

Group type: COMPARATOR
Intervention: Anthracycline + ATRA
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 285
Study: 21682121

Group type: EXPERIMENTAL
Intervention: 200 microg misoprostol
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 400 microg misoprostol (2x 200 microg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 600 microg misoprostol (3x 200 microg)
Number of subjects: 90
Study: 18647095

Group type: EXPERIMENTAL
Intervention: Low-intensity laser application at 780 nm (35 J/cm², 70 mW, 20 sec per site) during subgingival scaling and root planing.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-intensity laser application at 630 nm (8.8 J/cm², 35 mW, 10 sec) for healing after the procedure.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Visual analogue scale for pain assessment during the procedure.
Number of subjects: 10
Study: 17932854

Group type: EXPERIMENTAL
Intervention: Anterior chamber paracentesis (Group 1, 15 eyes)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No anterior chamber paracentesis (Group 2, 15 eyes)
Number of subjects: 30
Study: 12859691

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10872566

Group type: EXPERIMENTAL
Intervention: 50 mg losartan
Number of subjects: 273

Group type: COMPARATOR
Intervention: 50 mg atenolol
Number of subjects: 273
Study: 9171758

Group type: EXPERIMENTAL
Intervention: Frequent follow-up examinations (group 1)
Number of subjects: 597

Group type: COMPARATOR
Intervention: Virtually no follow-up (group 2)
Number of subjects: 597
Study: 8404183

Group type: EXPERIMENTAL
Intervention: High-resolution computed tomography (HRCT)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Chest radiography
Number of subjects: 134
Study: 3542850

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 100 mg b.i.d.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 500 mg b.i.d.
Number of subjects: 30
Study: 30358711

Group type: EXPERIMENTAL
Intervention: CYC‐PERT (cyclic combination therapy adding progesterone to estrogen)
Number of subjects: 1532

Group type: COMPARATOR
Intervention: CC‐PERT (continuous combined estrogen progestin therapy)
Number of subjects: 1532
Study: 27732013

Group type: EXPERIMENTAL
Intervention: Authentic pride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hubristic pride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hubristic pride with self-transcendent value affirmation
Number of subjects: 0
Study: 24375941

Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 21986390

Group type: EXPERIMENTAL
Intervention: Community outreach strategies including print materials and presentations at events
Number of subjects: 580
Study: 19775763

Group type: EXPERIMENTAL
Intervention: Allopurinol (loading dose 400 mg followed by 100 mg for 1 month)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 17914067

Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 15662054

Group type: EXPERIMENTAL
Intervention: Physiotherapy initial assessment and management
Number of subjects: 766

Group type: COMPARATOR
Intervention: Routine practice
Number of subjects: 766
Study: 12779015

Group type: EXPERIMENTAL
Intervention: Adjuvant autologous tumour cell-lysate vaccine (6 applications at 4-week intervals after radical nephrectomy)
Number of subjects: 558

Group type: COMPARATOR
Intervention: Control group (no adjuvant treatment)
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Adjuvant autologous tumour cell-lysate vaccine
Number of subjects: 558
Study: 10580024

Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (75 mg/m2) given for 2.5 years, interrupted every 6 weeks for treatment with either high-dose methotrexate or teniposide plus cytarabine.
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (75 mg/m2)
Number of subjects: 180
Study: 8904679

Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3) administered as a loading dose at various points during surgery and followed by continuous infusion.
Number of subjects: 68
Study: 1991426

Group type: EXPERIMENTAL
Intervention: Nd‐YAG laser phototherapy and CO2 laser treatment (Group A)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Closed Ferguson hemorrhoidectomy (Group B)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study: 6371293

Group type: EXPERIMENTAL
Intervention: 90 mg tobramycin (TOB) administered twice a day for 10 days
Number of subjects: 85

Group type: COMPARATOR
Intervention: 60 mg tobramycin (TOB) administered three times a day for 10 days
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 90 mg tobramycin (TOB) for bacterial pneumonia and lung abscess
Number of subjects: 85

Group type: COMPARATOR
Intervention: 60 mg tobramycin (TOB) for bacterial pneumonia and lung abscess
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 90 mg tobramycin (TOB) against chronic RTI
Number of subjects: 85

Group type: COMPARATOR
Intervention: 60 mg tobramycin (TOB) against chronic RTI
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: 90 mg tobramycin (TOB) against chronic bronchitis
Number of subjects: 85

Group type: COMPARATOR
Intervention: 60 mg tobramycin (TOB) against chronic bronchitis
Number of subjects: 85
Study: 31329470

Group type: EXPERIMENTAL
Intervention: Education + on-road training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Education alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Education + on-road + simulator training
Number of subjects: 40
Study: 29347988

Group type: EXPERIMENTAL
Intervention: Melatonin (2 mg, Circadin®)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 33
Study: 26305067

Group type: EXPERIMENTAL
Intervention: PNPLA3 CG/GG SNP at rs738409
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: PNPLA3 CG/GG genotype
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: PNPLA3 genotype
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: rs738409 SNP in PNPLA3
Number of subjects: 937
Study: 25219475

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided needling with subacromial corticosteroid injection
Number of subjects: 54

Group type: COMPARATOR
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 54
Study: 22933480

Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) administration of PHQ-9
Number of subjects: 51

Group type: COMPARATOR
Intervention: Paper-and-pencil administration of PHQ-9
Number of subjects: 51
Study: 21298836

Group type: EXPERIMENTAL
Intervention: 1550 nm Erbium fiber laser treatment, once a week for 8 successive treatments
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (untreated half of the forehead)
Number of subjects: 20
Study: 17397112

Group type: EXPERIMENTAL
Intervention: quantile approximation method
Number of subjects: 0

Group type: COMPARATOR
Intervention: random effects approach (DerSimonian and Laird)
Number of subjects: 0
Study: 16244020

Group type: EXPERIMENTAL
Intervention: Local anesthetic (20 mL of 2% lidocaine) administered through the epidural needle before catheter insertion
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (catheter group) with local anesthetic injected via the catheter after catheter insertion
Number of subjects: 240
Study: 12438292

Group type: EXPERIMENTAL
Intervention: Subjects with high-normal arterial pressure (systolic pressure 133 mm Hg)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Subjects with hypertensive arterial pressure (systolic pressure 163 mm Hg)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Response to standing in subjects with high-normal arterial pressure
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Correlation analysis across all groups
Number of subjects: 300
Study: 10806942

Group type: EXPERIMENTAL
Intervention: GC Fuji Ortho glass ionomer cement (GC Industrial Co., Tokyo, Japan)
Number of subjects: 38

Group type: COMPARATOR
Intervention: System 1+ composite resin (Ormco Corp., Glendora, CA)
Number of subjects: 38
Study: 7491367

Group type: EXPERIMENTAL
Intervention: Ginkobene (3 x 40 mg daily for 57 days)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 2255512

Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty (ALT)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Timolol maleate 0.5%
Number of subjects: 271
Study: 461778

Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 12765
Study: 30102438

Group type: EXPERIMENTAL
Intervention: Radiomic signature based on sagittal T1 CE and T2 MRI sequences
Number of subjects: 143
Study: 28380053

Group type: EXPERIMENTAL
Intervention: ToyBox-intervention
Number of subjects: 2434

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2434
Study: 25742529

Group type: EXPERIMENTAL
Intervention: Workplace fitness and education program (4 months of exercise training in 15-minute sessions)
Number of subjects: 60
Study: 23707312

Group type: EXPERIMENTAL
Intervention: Anodal tDCS of M1 (2 mA, 15 min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS of PPC (2 mA, 15 min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS (control group)
Number of subjects: 0
Study: 21802939

Group type: EXPERIMENTAL
Intervention: Gefitinib 250mg/d
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 19457670

Group type: EXPERIMENTAL
Intervention: Loading of an outstretched arm (weight dropped into a receptacle)
Number of subjects: 19
Study: 16923090

Group type: EXPERIMENTAL
Intervention: GIK (50% dextrose in 500 ml of water; regular insulin, 125 IU; potassium, 80 mmol) at 0.75 ml/kg/h
Number of subjects: 82

Group type: COMPARATOR
Intervention: 5% dextrose in water
Number of subjects: 82
Study: 15295413

Group type: EXPERIMENTAL
Intervention: Rubidium 82 PET quantification of perfusion reserve
Number of subjects: 23
Study: 11806646

Group type: EXPERIMENTAL
Intervention: 10% strontium chloride
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2% sodium fluoride
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 40% formalin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 5% potassium nitrate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (triple distilled water)
Number of subjects: 10
Study: 9801529

Group type: EXPERIMENTAL
Intervention: Efficacy enhancing interventions (role modeling, verbal persuasion, physiological feedback)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 77
Study: 7712668

Group type: EXPERIMENTAL
Intervention: Concomitant therapy (regimen A): 60 mg/kg intravenous foscarnet and 3.75 mg/kg ganciclovir
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Daily alternating therapy (regimen B): 120 mg/kg foscarnet and 6 mg/kg ganciclovir
Number of subjects: 13
Study: 2664883

Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Number of subjects: 45

Group type: COMPARATOR
Intervention: L‐5‐hydroxytryptophan (L‐5HTP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Nomifensine
Number of subjects: 45
Study: 705283

Group type: EXPERIMENTAL
Intervention: Physical training with maximum intensity (interval training 2 X 60 min a week for 12 months)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (untrained)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Physical training with maximum intensity
Number of subjects: 15
Study: 31991513

Group type: EXPERIMENTAL
Intervention: High-dose nitroglycerin (5 µg·kg‐1 ·min‐1)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Low-dose nitroglycerin (1 µg·kg‐1 ·min‐1)
Number of subjects: 42
Study: 31093677

Group type: EXPERIMENTAL
Intervention: GM1 (80 mg, day -1 to day 2)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study: 28355756

Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5 mg/kg intravenously before induction and followed by 2.0 mg·kg(‐1)·h(‐1) to the end of surgery
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lidocaine group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 25474182

Group type: EXPERIMENTAL
Intervention: Brody CT scores
Number of subjects: 60
Study: 23529800

Group type: EXPERIMENTAL
Intervention: Minodronate 1 mg once a day for 24 months
Number of subjects: 704

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 704
Study: 21253777

Group type: EXPERIMENTAL
Intervention: Cinacalcet treatment for 12 months
Number of subjects: 320
Study: 19938933

Group type: EXPERIMENTAL
Intervention: Bartenders trained in responsible beverage service programs
Number of subjects: 596

Group type: COMPARATOR
Intervention: Control bartenders (not trained)
Number of subjects: 596
Study: 16165158

Group type: EXPERIMENTAL
Intervention: Venlafaxine (75-225mg/day)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20-60mg/day)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study: 15529377

Group type: EXPERIMENTAL
Intervention: MTX-3 mg/kg infliximab
Number of subjects: 1049

Group type: EXPERIMENTAL
Intervention: MTX-6 mg/kg infliximab
Number of subjects: 1049

Group type: COMPARATOR
Intervention: MTX-placebo
Number of subjects: 1049
Study: 11527433

Group type: EXPERIMENTAL
Intervention: Verification of properties using local representation (e.g., verifying 'mane' for PONY after verifying 'mane' for HORSE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verification of properties using global representation (e.g., verifying 'mane' for PONY after verifying 'mane' for LION)
Number of subjects: 0
Study: 9692703

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) 400 mg b.d. for 4 weeks + clarithromycin 500 mg b.d. (Group A)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) 400 mg b.d. for 4 weeks + clarithromycin 500 mg t.d.s. (Group B)
Number of subjects: 273
Study: 30105991

Group type: EXPERIMENTAL
Intervention: Adapalene 0.3% gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tretinoin 0.05% cream
Number of subjects: 0
Study: 29096681

Group type: EXPERIMENTAL
Intervention: SlowMo intervention added to treatment as usual (TAU)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 360
Study: 26237622

Group type: EXPERIMENTAL
Intervention: Magnesium (Mg) therapy, 50 mg/kg bolus immediately after induction of anesthesia followed by another 50 mg/kg infusion over 3 hours (total dose, 100 mg/kg)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Magnesium (Mg) therapy
Number of subjects: 363
Study: 23759000

Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation (RSD)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Antiarrhythmic drugs (AAD)
Number of subjects: 200
Study: 19067437

Group type: EXPERIMENTAL
Intervention: Multiple suicide attempts
Number of subjects: 121

Group type: COMPARATOR
Intervention: One or no suicide attempts
Number of subjects: 121
Study: 17604955

Group type: EXPERIMENTAL
Intervention: Modified Blalock-Taussig (BT) shunt
Number of subjects: 17

Group type: COMPARATOR
Intervention: Right ventricle to pulmonary artery (RV-PA) conduit
Number of subjects: 17
Study: 15453909

Group type: EXPERIMENTAL
Intervention: Psyllium hydrophilic mucilloid (12.7 g daily) taken in the morning
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Psyllium hydrophilic mucilloid (12.7 g daily) taken in the evening
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (no psyllium administration)
Number of subjects: 63
Study: 11268113

Group type: EXPERIMENTAL
Intervention: 10% peppermint oil
Number of subjects: 41

Group type: COMPARATOR
Intervention: 1% peppermint oil
Number of subjects: 41

Group type: COMPARATOR
Intervention: 0.5% peppermint oil
Number of subjects: 41

Group type: COMPARATOR
Intervention: 0.1% peppermint oil
Number of subjects: 41

Group type: COMPARATOR
Intervention: 0% peppermint oil
Number of subjects: 41
Study: 9640160

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.025 microgram kg‐1 min‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.1 microgram kg‐1 min‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol infusion rate 6 mg kg‐1 h‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.025‐0.05 microgram kg‐1 min‐1
Number of subjects: 0